In June 2026, Alkermes plc reported detailed positive phase 2 Vibrance‑2 results for its oral orexin 2 receptor agonist ...

The FDA granted the status to alixorexton for idiopathic hypersomnia while the EC approved the designation for narcolepsy.

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...

— First Large Phase 2 Study of an Orexin 2 Receptor Agonist to Demonstrate Clinically Meaningful and Statistically Significant Improvements in Wakefulness and Excessive Daytime Sleepiness Compared to ...

Avadel acquisition adds LUMRYZ sales momentum; alixorexton Phase 2/3 data supports growth. Click for this ALKS stock update.

In a report released yesterday, Benjamin Burnett from Wells Fargo maintained a Buy rating on Alkermes, with a price target of $65.00. Unlock powerful investing tools and data-driven insights with ...

Alkermes (NASDAQ:ALKS) is gearing up to announce its quarterly earnings on Thursday, 2024-10-24. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...

View Alkermes Public Limited Company ALKS stock quote prices, financial information, real-time forecasts, and company news from CNN.

A month has gone by since the last earnings report for Alkermes (ALKS Quick Quote ALKS - Free Report) . Shares have lost about 2.6% in that time frame, outperforming the S&P 500. Will the recent ...

Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its inaugural Alkermes Pathways APN Research Awards™ program on Monday, March 16, 2026. This competitive grant ...

DUBLIN, Oct. 31, 2023 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the Registration Statement on Form 10, as amended (Form 10), filed by Mural Oncology plc (Mural Oncology) was ...